Join the Oncology Voice Network. Join for Free
The ART of Excellence... How to be a Rock Star MSL
medical affairs industry writing process adaptability resilience MSLs

The ART of Excellence... How to be a Rock Star MSL


Share This Article


Summary

In this episode, Cathy Andorfer joins Tom Caravela to discuss her new book and the journey of writing it. Cathy shares insights into her writing process, addressing challenges and the evolving landscape of the medical affairs industry. The conversation highlights the significance of adaptability and resilience for MSLs, along with maintaining a positive mindset amidst industry changes. Cathy reflects on the importance of these traits in her career and provides a glimpse into future industry trends. The episode wraps up with expressions of gratitude and a reminder about the upcoming Mass West event, followed by credits and sponsor information.

In this week’s episode, Cathy Andorfer, National MSL Director shares The ART of Excellence…How to become a Rock Star MSL

Click for Source
medical affairs industry, writing process, adaptability, resilience, MSLs

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Healthy on the Road-How to Avoid MSL Belly
Partner Avatar MSL Talk: Tom Caravela, Alex Palumbo

Healthy on the Road-How to Avoid MSL Belly

Podcast
The Strategic vs the Scientific MSL
Partner Avatar MSL Talk: Tom Caravela, Joy Morrell

The Strategic vs the Scientific MSL

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Explore OVN